These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
On track to complete the BLA submission in the first half of 2022
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
The target demographic will be those between the ages of 30 and 65 years
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The hospital has recently launched Radionuclide therapy
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
2022 is going to be the year of opportunities and innovations from the medical industry in India
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Subscribe To Our Newsletter & Stay Updated
